The Cooper Companies, Inc. (COO)

Healthcare
Medical Instruments & Supplies
United States
Yahoo Finance  •  Trading View  •  Company site
Price
$81.57
▲ 0.09 (0.11%)
Market Cap
$16,216,844,288
Shares: 199,414,893.617
P/E
N/A
P/B: N/A
ROE
4.55%
Current Ratio: 1.89
Fundamentals Score
71 (POSITIVE)

Company Overview

The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical, toric, and multifocal contact lenses that address vision challenges, such as astigmatism, presbyopia, and myopia. Its CooperSurgical segment focuses on family and women's health care, which provides fertility products and services, medical devices, and contraception, as well as cryostorage, such as cord blood and cord tissue storage. This segment offers Paragard, a hormone-free intrauterine device; and fertility consumables and equipment, donor gamete services, and genomic services, including genetic testing. The company sells its products to distributors, group purchasing organizations, eye care and health care professionals, including independent practices, corporate retailers, hospitals and clinics, and authorized resellers. The Cooper Companies, Inc. was founded in 1958 and is headquartered in San Ramon, California.

Headquarters: 6101 Bollinger Canyon Road, San Ramon, CA, 94583, United States  |  Employees: 15000  |  Website: coopercos.com
Key Contacts
IR / Phone: 925 460 3600
Exchange: NMS
Industry: Medical Instruments & Supplies
Quick Financial Snapshot
Revenue$4,092,400,000
Net Income$374,900,000
Free Cash Flow$423,200,000
Book Value / ShareN/A

Balance Sheet & Liquidity

Total Liabilities$4,155,700,000
Total Equity$8,239,100,000
Debt / EquityN/A
Current Ratio1.89
Interest CoverageN/A
Working CapitalN/A

Valuation Metrics

Core multiples and valuation signals — useful to compare vs peers.

P/E (TTM)N/A
Industry P/EN/A
Forward P/E16.46
P/BN/A
Price / SalesN/A
P / FCFN/A
EV / EBITDAN/A
Graham NumberN/A
DCF (placeholder)
Notes: red items typically indicate expensive multiples relative to fundamentals. Use the "Compare with industry" tool for context.

EPS (Annual)

Financial Performance

Revenue vs Net Income

Free Cash Flow (annual)

Profitability & Efficiency

Gross Margin 65.54%
Operating Margin N/A
Net Margin N/A
ROIC N/A
Asset Turnover N/A

Automated Fundamental Signals (Score: 71)

Passed
  • EPS shows upward trend
  • EPS CAGR 37.89%
  • Price CAGR 6.43%
  • Gross Margin 65.5%
  • Debt/Equity ratio
  • Operating Margin 16.7%
  • Positive Free Cash Flow
  • Current Ratio
Failed
  • CapEx intensity
  • Debt/EBITDA
  • DCF valuation (Overvalued)

Price Chart (Candlestick)

Technical Analysis (Score: 65)

RSI (14)51.85
SMA 5081.26
SMA 20074.76
MACD-0.02
Signal NEUTRAL
RSI 51.9, SMA trend bullish, momentum -12.9%.

Governance & Management

Governance scores: Audit: 10 | Board: 2 | Compensation: 7 | Shareholder Rights: 3
Executive Team
NameTitle
Mr. Albert G. White III President, CEO & Non-Independent Director (1970)
Mr. Brian G. Andrews Executive VP, CFO, Treasurer & Principal Accounting Officer (1979)
Mr. Daniel G. McBride Esq. Executive VP & COO (1964)
Ms. Holly R. Sheffield President of CooperSurgical, Inc. (1971)
Mr. Gerard H. Warner III President of CooperVision, Inc. (1965)
Mr. Kim Duncan Vice President of Investor Relations & Risk Management (—)
Mr. Nicholas S. Khadder J.D. General Counsel & Secretary (1974)
Mr. Agostino Ricupati CPA Senior Vice President & Tax (1967)
Governance data last updated: 2/1/2026

Latest News

No news available for this company.

← Back